\n
\n
Obesity remains one of Saudi Arabia\u2019s most pressing health issues. Nearly one in three people living with obesity also suffer from cardiovascular complications\u2014placing a heavy burden on families, healthcare services, and the national economy.
\nAt \u201cBeyond the scale\u201d conference in Riyadh today, The Saudi Scientific Diabetes Society (SSDS) and the Saudi Society for the Study of Obesity (SSSO) along with several esteemed local societies & healthcare leaders discussed the latest strategies to tackle this growing challenge.
\nCentral to the discussions was the call to expand awareness and access to advanced therapies such as GLP-1, which when treating obesity, it is important not to focus only on weight loss but also reduce the risks of obesity-related complications including cardiovascular disease, type 2 diabetes, chronic kidney disease, and fatty liver diseases.
\n\u201cObesity is a chronic disease with far-reaching consequences. Innovative therapies such as semaglutide are transforming the way we treat it\u2014not only as an issue of weight, but as a strategy to prevent serious, life-threatening CV complications,\u201d added Prof. Abdulrahman Alshaikh, President of the SSDS.
\nOther participating societies supported the cause & reaffirmed their commitment to advancing awareness, education, and equitable access to effective obesity solutions in partnership with Novo Nordisk and other key stakeholders.<\/p>\n
The event also highlighted \u201cSAHIM\u201d Initiative \u2014 launched by the Saudi Scientific Diabetes Society and the Saudi Society for the Study of Obesity \u2014 which unites doctors, scientific societies, and policymakers to reshape how obesity is diagnosed and treated nationwide. Experts described the initiative as \u201cchanging the state of the nation with SAHIM.\u201d<\/p>\n
In line with the same cause & the inspiring 2030 vision to strengthen drug security for diabetes and obesity treatments, Global healthcare leader Novo Nordisk announced localising the manufacturing of semaglutide in Saudi Arabia\u2019s to support the kingdom healthcare transformational goals.<\/p>\n
With these combined efforts, Saudi Arabia is positioning itself at the forefront of innovation, collaboration, and patient access in\u00a0obesity\u00a0care.<\/p>\n","protected":false},"excerpt":{"rendered":"
Obesity remains one of Saudi Arabia\u2019s most pressing health issues. Nearly one in three people living with obesity also suffer from cardiovascular complications\u2014placing a heavy burden on families, healthcare services, and the national economy. At \u201cBeyond the scale\u201d conference in Riyadh today, The Saudi Scientific Diabetes Society (SSDS) and the Saudi Society for the Study …<\/p>\n","protected":false},"author":2,"featured_media":119743,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[439],"tags":[],"class_list":["post-119745","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-english-news"],"yoast_head":"\n